A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints

• Status: Completed
• Trial end date: 2009-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether Tanakan® is effective at slowing the progression from memory complaint to dementia of Alzheimer's type.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ipsen

Criteria

Inclusion Criteria:

• Spontaneously reporting a memory complaint

• Short anxiety battery test < 6, (only if patient screened at GP site)

• Geriatric depression scale < 15

• Mini-mental state (MMS) > 25 in GP's office (in hospital site MMS is done as complementary scale)

Exclusion Criteria:

• Objective memory impairment

• Clinician rated dementia staging system > 0.5

• Mini-mental state < 25

• Dementia, past history of seizures, Parkinson disease